Archives

Today, the U.S. Food and Drug Administration (FDA) approved Zolgensma (onasemnogene abeparvovac-xioi), the first gene therapy for a neuromuscular disease. Zolgensma is a one-time intravenous (into the vein) infusion for the…

Earlier this week, JAMA Neurology published an article co-authored by Muscular Dystrophy Association (MDA) staff members that addresses the role of newborn screening (NBS) in the field of neuromuscular disease.…

Just two weeks before her 28th birthday, and after a long search for an explanation for a series of symptoms, Sunny Brous was diagnosed with amyotrophic lateral sclerosis (ALS). Sunny…

Amyotrophic lateral sclerosis (ALS) is a neuromuscular degenerative disease that causes rapid muscular atrophy. It progresses quickly, and patients need access to all available support as soon as possible. Currently,…

Dr. Jonathan Glass is the director of the Emory ALS Center, co-chair of the Northeast ALS Consortium, and professor of Neurology and Pathology at Emory University in Atlanta. Dr. Glass’…

In 2015, Karen Condron was honored with MDA’s prestigious Wings Over Wall Street Spirit Award in recognition of her passion for life — while fighting amyotrophic lateral sclerosis (ALS). It…

While most visits to the doctor lead to a quick diagnosis, the same is not so for amyotrophic lateral sclerosis (ALS). On average, getting an ALS diagnosis takes 12 months…

Team Momentum is a team of runners who dedicate their miles to help our community raise critical dollars that help MDA fund research breakthroughs and provide families living with muscle…

Pat Quinn, co-founder of the ALS Association’s Ice Bucket Challenge, has been advocating for ALS awareness, treatments and a cure since his diagnosis with amyotrophic lateral sclerosis (ALS) in 2013.…

John Schwall, chief operating officer and co-founder of IEX, shares a personal connection in the fight against amyotrophic lateral sclerosis (ALS) as his mother suffered a six-year battle with the…